• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Hypertension: ReCor charges ahead with ultrasound renal denervation

Hypertension: ReCor charges ahead with ultrasound renal denervation

January 28, 2014 By Arezu Sarvestani

Hypertension: ReCor charges ahead with ultrasound renal denervation

California-based ReCor Medical wasn’t deterred by the tumult in renal denervation following Medtronic’s (NYSE:MDT) disappointing clinical trial, vowing to proceed with commercial efforts for its Paradise System for treating hypertension.

ReCor’s technology uses ultrasound rather than radiofrequency energy, and the company deemed its system sufficiently different from Medtronic’s and others to merit continued progress.

"Having reviewed our own clinical results and spoken to clinicians who have collectively treated hundreds of patients with resistant hypertension using different RDN systems, ReCor is convinced that our product is well-differentiated from these RF-based approaches," ReCor president & CEO Andrew Weiss said in prepared remarks. "We remain convinced that RDN has the potential to become a key component of HTN therapy, and believe that our Paradise System provides the safe, reliable and complete denervation needed to become the category leader in this field."

ReCor just last month won CE Mark approval in the European Union, with the 1st patients already treated in Germany, and the company also announced initial use of its Radiance line of radial-access-friendly catheters.

The Paradise System is the only CE Marked renal denervation system using ultrasound energy, with rival devices from Medtronic, Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ) all using radiofrequency energy to ablate the nerves lining the renal arteries, which are believed to contribute to hypertension.

Hopes for the renal denervation market plunged earlier this month with the surprise announcement that the U.S. trial for Medtronic‘s (NYSE:MDT) Symplicity RDN device missed its primary efficacy endpoint. Full results from the trial are slated to drop at the American College of Cardiology conference in late March. The news came as a shock to the industry; an FDA nod for the Symplicity device once seemed to be such a lock that St. Jude suspended a U.S. trial of its Enlightn renal denervation entry.

Both St. Jude and Boston Scientific, which got into RDN with the $130 million buyout of Vessix last year, said last week that they were still bullish on the technology in hard-to-treat high blood pressure cases. But Boston still decided to delay the Vessix program until more is known about the Symplicity miss, CEO Michael Mahoney said.

Last week Covidien (NYSE:COV) announced that it would wind down development of its OneShot renal denervation device, which already had E.U. regulatory approval, meaning the closure of Covidien’s Rapid II trial.

Filed Under: News Well Tagged With: CE Mark, Hypertension, ReCor Medical, Renal

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy